Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Galmed Pharmaceuticals Ltd. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −3 vs. Q3 2023
- Shares held
- 547.0K
- −144.4K (−20.9%) vs. Q3 2023
- Total value
- $248.8K
- −$179.4K (−41.9%) vs. Q3 2023
- New holders
- 0
- 2 more added
- Sold out
- 3
- 4 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EOCN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $85.9K |
| Q1 2026 | 16 | $71.2K |
| Q4 2025 | 17 | $166.4K |
| Q3 2025 | 14 | $102.0K |
| Q2 2025 | 15 | $140.2K |
| Q1 2025 | 13 | $80.4K |
| Q4 2024 | 12 | $142.8K |
| Q3 2024 | 10 | $38.3K |
| Q2 2024 | 13 | $112.9K |
| Q1 2024 | 13 | $57.6K |
| Q4 2023 | 14 | $248.8K |
| Q3 2023 | 17 | $428.2K |
| Q2 2023 | 12 | $419.1K |
| Q1 2023 | 21 | $878.3K |
| Q4 2022 | 22 | $1.21M |
| Q3 2022 | 25 | $803.6K |
| Q2 2022 | 22 | $1.70M |
| Q1 2022 | 23 | $4.47M |
| Q4 2021 | 24 | $7.05M |
| Q3 2021 | 26 | $11.8M |
| Q2 2021 | 25 | $14.6M |
| Q1 2021 | 30 | $19.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Galmed Pharmaceuticals Ltd.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CVI Holdings, LLC | 269,238 | $122.5K | 0.25% | +19,854+8.0% | Added |
| Walleye Capital LLC | 115,400 | $52.5K | 0.00% | −134,363−53.8% | Reduced |
| Morgan Stanley | 82,468 | $37.5K | 0.00% | +62,436+311.7% | Added |
| Two Sigma Advisers, LP | 44,433 | $20.2K | 0.00% | −6,200−12.2% | Reduced |
| Two Sigma Investments, LP | 23,516 | $10.7K | 0.00% | −7,204−23.5% | Reduced |
| Citadel Advisors LLC | 11,251 | $5.12K | 0.00% | −29,207−72.2% | Reduced |
| Wells Fargo & Company | 204 | $93 | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 167 | $76 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 53 | $24 | 0.00% | 00.0% | Unchanged |
| Bourgeon Capital Management LLC | 34 | $16 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 17 | $8 | 0.00% | 00.0% | Unchanged |
| ZRC Wealth Management, LLC | 7 | $5 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1 | $0 | 0.00% | 00.0% | Unchanged |
| TSFG, LLC | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 0 | $0 | 0.00% | −29,608−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −20,130−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −28−100.0% | Sold out |